Amarin Corp ADR (AMRN)

$13.97 -0.10 (-0.71%)
Market Cap 295.09M
Revenue (ttm) 213.65M
Net Income (ttm) -38.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.16%
Debt to Equity Ratio 0.00
Volume 78,100
Avg Vol 79,494
Day's Range N/A - N/A
Shares Out 21.12M
Stochastic %K 12%
Beta 0.81
Analysts Hold
Price Target $13.33

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 353 0 166 99020
Address:
One Central Plaza, 8th Floor 36 Dame Street, Dublin, Ireland
NotAgain2024
NotAgain2024 Aug. 30 at 3:08 PM
$AMRN give me my money back!!!!
0 · Reply
NilsSB
NilsSB Aug. 30 at 2:25 PM
$AMRN the economy is tanking - if we aren’t cash flow positive in 18 months, we may drop below $10
1 · Reply
CaptBeer
CaptBeer Aug. 30 at 1:10 PM
$AMRN Up to 30% Event Reduction if you stay on your IPE treatment for at least 1.5 years AND it persists even AFTER cessation! https://x.com/GeoWizz_/status/2094049115495698449
2 · Reply
CaptBeer
CaptBeer Aug. 29 at 9:00 PM
$AMRN At very high triglyceride levels, the priority shifts toward pancreatitis prevention. And one important reminder: Lowering triglycerides does not automatically mean lowering cardiovascular events. That is why icosapent ethyl should not be viewed as interchangeable with generic omega-3 products. https://lnkd.in/p/gTxQZj2N
0 · Reply
CaptBeer
CaptBeer Aug. 29 at 7:06 PM
$AMRN Eddingpharm, our Partner in China just released H1 Sales Figures for 2026: VASCEPA sales jumped 144% in 2025, from RMB 77.5M to RMB 189.1M. Even more impressive, China in-market volume was reportedly up approximately 90% YTD in 2026. The potential game changer is NRDL inclusion, which I believe is increasingly likely for 2027. If that happens, VASCEPA moves from primarily private-market access toward national reimbursement covering roughly 98% of China's population. The VASCEPA/VAZKEPA story is increasingly becoming an international growth story — and 2027 could be the inflection point. Europe/Recordati: VAZKEPA in-market demand was up approximately 69% in Q2 2026, yet Recordati has only begun rolling out the product across its territory. Canada/HLS: A much more mature market but still growing. HLS reported VASCEPA sales up 15% in Q1 2026, with unit volume up 18%. Here’s an Economic Model for 2026-2030 that you can hang your hat on! Peruse the Key Takeaways in this Illustration.
2 · Reply
EnVila
EnVila Aug. 29 at 9:22 AM
$AMRN VASCEPA’s revenue in China for the first half of 2026 reached ca. $12.7 million (RMB 85.9 million), according to Edding’s "Interim Results Announcement for the Six Months Ended 30 June 2026" released yesterday. "The gross sales revenue from the Group’s innovative drug increased by 52.2% from RMB76.1 million for the six months ended 30 June 2025 to RMB115.7 million for the Reporting Period. Of this amount, RMB85.9 million was derived from Vascepa, representing an increase of RMB13.6 million, or 18.8%, as compared with the six months ended 30 June 2025, primarily attributable to the Group’s enhanced sales and marketing efforts." https://qiniu.mfdemo.cn/yiteng/2026/08/28/tEyT6nzwDwKww.pdf
1 · Reply
CaptBeer
CaptBeer Aug. 28 at 11:09 PM
$AMRN Adherence and Legacy Effects of High Dose Eicosapentaenoic Acid in Hypertriglyceridemia and High CV Risk – REDUCE-IT Legacy https://www.amarincorp.com/news-releases/news-release-details/new-reduce-itr-legacy-analysis-presented-european-society
0 · Reply
Patrick2343
Patrick2343 Aug. 28 at 3:41 PM
$AMRN jron says wait for the new formulation only a few years away
0 · Reply
NotAgain2024
NotAgain2024 Aug. 28 at 3:29 PM
$AMRN jaja alll bull shittoo till the stock pays
0 · Reply
CostanzaGeorge
CostanzaGeorge Aug. 28 at 3:25 PM
$AMRN China market is doing better than the recent Amarin earnings have shown. Edding front loaded supply so they have not made a supply purchase in 6 consecutive quarters. First half of 2026 sales were about $12.7M which was up from $10.7M in first half of 2025. For reference, Recordati first half 2026 sales were about $16.2M. This shows there is another large market growing along with EU even with China being private pay only. Link to the report: https://qiniu.mfdemo.cn/yiteng/2026/08/28/tEyT6nzwDwKww.pdf
2 · Reply
Latest News on AMRN
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

Aug 28, 2026, 8:15 AM EDT - 2 days ago

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Aug 24, 2026, 8:15 AM EDT - 6 days ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Amarin reinstated with an Underweight at JPMorgan

2026-08-21T10:35:41.000Z - 9 days ago

Amarin reinstated with an Underweight at JPMorgan

Amarin Corporation Transcript: Transcript

Aug 4, 2026, 11:41 PM EDT - 26 days ago

Amarin Corporation Transcript: Transcript

Amarin Corporation Slides

Jul 30, 2026, 4:08 AM EDT - 4 weeks ago

Amarin Corporation Slides

Amarin Corporation Quarterly report

Jul 29, 2026, 4:31 PM EDT - 4 weeks ago

Amarin Corporation Quarterly report

Amarin Corporation Earnings release

Jul 29, 2026, 7:19 AM EDT - 4 weeks ago

Amarin Corporation Earnings release

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Jul 29, 2026, 7:00 AM EDT - 4 weeks ago

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Jul 15, 2026, 8:00 AM EDT - 6 weeks ago

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Amarin Corporation Transcript: Transcript

Jul 8, 2026, 3:21 PM EDT - 7 weeks ago

Amarin Corporation Transcript: Transcript

Amarin Corporation Transcript: Transcript

Jul 8, 2026, 12:06 PM EDT - 7 weeks ago

Amarin Corporation Transcript: Transcript

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

Jun 30, 2026, 4:15 PM EDT - 2 months ago

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

May 27, 2026, 8:00 AM EDT - 3 months ago

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

Amarin Corporation Transcript: Transcript

Apr 29, 2026, 10:05 AM EDT - 4 months ago

Amarin Corporation Transcript: Transcript

Amarin Corporation Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Amarin Corporation Slides: Corporate presentation

Amarin Reports 2026 First Quarter Financial Results

Apr 29, 2026, 7:00 AM EDT - 4 months ago

Amarin Reports 2026 First Quarter Financial Results

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

Amarin highlights new recommendation for treatment of CV risk

2026-03-18T12:41:54.000Z - 5 months ago

Amarin highlights new recommendation for treatment of CV risk

Amarin to present data in patients at extreme cardiovascular risk

2026-03-16T12:27:24.000Z - 5 months ago

Amarin to present data in patients at extreme cardiovascular risk

Amarin highlights recent data published on REDUCE-IT study

2026-03-02T13:26:30.000Z - 6 months ago

Amarin highlights recent data published on REDUCE-IT study

Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities

2026-02-25T12:14:50.000Z - 6 months ago

Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities

Amarin issues call to action for American Heart Month

2026-02-23T13:23:34.000Z - 6 months ago

Amarin issues call to action for American Heart Month

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Feb 23, 2026, 8:00 AM EST - 6 months ago

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

US Supreme Court to hear 'skinny label' patent fight involving Amarin

Jan 16, 2026, 2:44 PM EST - 8 months ago

US Supreme Court to hear 'skinny label' patent fight involving Amarin

Amarin comments on recent innovations for patients with elevated triglycerides

2026-01-09T12:13:43.000Z - 8 months ago

Amarin comments on recent innovations for patients with elevated triglycerides

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

Jan 9, 2026, 7:00 AM EST - 8 months ago

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

Amarin expects Q4 net revenue $48M-$43M

2026-01-08T12:06:26.000Z - 8 months ago

Amarin expects Q4 net revenue $48M-$43M

Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

2025-11-10T00:10:10.000Z - 10 months ago

Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 9, 2025, 4:15 PM EST - 10 months ago

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Nov 3, 2025, 8:30 AM EST - 10 months ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Amarin reports Q3 EPS (2c) vs (6c) last year

2025-10-29T11:11:18.000Z - 10 months ago

Amarin reports Q3 EPS (2c) vs (6c) last year

Amarin issues statement related to recent action by FDA for fenofibrate drugs

2025-10-27T12:05:31.000Z - 10 months ago

Amarin issues statement related to recent action by FDA for fenofibrate drugs

Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

2025-10-14T12:10:55.000Z - 11 months ago

Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Amarin presents new REDUCE-IT analyses

2025-09-01T12:30:11.000Z - 1 year ago

Amarin presents new REDUCE-IT analyses

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 31, 2025, 8:30 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 30, 2025, 8:30 AM EDT - 1 year ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Amarin announces upcoming presentations at ESC Congress 2025

2025-08-25T12:05:06.000Z - 1 year ago

Amarin announces upcoming presentations at ESC Congress 2025

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Aug 25, 2025, 8:00 AM EDT - 1 year ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Amarin expects accelerated in-market demand in Europe

2025-07-30T11:11:52.000Z - 1 year ago

Amarin expects accelerated in-market demand in Europe

Amarin Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2025 Financial Results

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jul 23, 2025, 7:30 AM EDT - 1 year ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Amarin announces exclusive license, supply agreement with Recordati

2025-06-24T11:05:33.000Z - 1 year ago

Amarin announces exclusive license, supply agreement with Recordati

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

Jun 24, 2025, 7:05 AM EDT - 1 year ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 29, 2025, 4:15 PM EDT - 1 year ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 28, 2025, 4:15 PM EDT - 1 year ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Apr 7, 2025, 7:30 AM EDT - 1 year ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 12:45 PM EDT - 1 year ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 19, 2025, 7:30 AM EDT - 1 year ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 27, 2025, 9:00 AM EST - 1 year ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Feb 19, 2025, 8:30 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Amarin Appoints Peter Fishman Chief Financial Officer

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Sep 9, 2024, 7:30 AM EDT - 2 years ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Aug 22, 2024, 8:30 AM EDT - 2 years ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 4:15 PM EDT - 2 years ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 17, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jul 8, 2024, 7:30 AM EDT - 2 years ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 7, 2024, 7:16 PM EDT - 2 years ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Amarin Board of Directors Announces CEO Transition

Jun 4, 2024, 7:30 AM EDT - 2 years ago

Amarin Board of Directors Announces CEO Transition

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 28, 2024, 8:15 AM EDT - 2 years ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 6, 2024, 8:00 AM EDT - 2 years ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Amarin Reports First Quarter 2024 Business Update and Financial Results

May 1, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 24, 2024, 2:00 PM EDT - 2 years ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Amarin Announces Results of Annual General Meeting of Shareholders

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 6, 2024, 3:30 PM EDT - 2 years ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 7:00 AM EST - 2 years ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Feb 15, 2024, 8:00 AM EST - 2 years ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

NotAgain2024
NotAgain2024 Aug. 30 at 3:08 PM
$AMRN give me my money back!!!!
0 · Reply
NilsSB
NilsSB Aug. 30 at 2:25 PM
$AMRN the economy is tanking - if we aren’t cash flow positive in 18 months, we may drop below $10
1 · Reply
CaptBeer
CaptBeer Aug. 30 at 1:10 PM
$AMRN Up to 30% Event Reduction if you stay on your IPE treatment for at least 1.5 years AND it persists even AFTER cessation! https://x.com/GeoWizz_/status/2094049115495698449
2 · Reply
CaptBeer
CaptBeer Aug. 29 at 9:00 PM
$AMRN At very high triglyceride levels, the priority shifts toward pancreatitis prevention. And one important reminder: Lowering triglycerides does not automatically mean lowering cardiovascular events. That is why icosapent ethyl should not be viewed as interchangeable with generic omega-3 products. https://lnkd.in/p/gTxQZj2N
0 · Reply
CaptBeer
CaptBeer Aug. 29 at 7:06 PM
$AMRN Eddingpharm, our Partner in China just released H1 Sales Figures for 2026: VASCEPA sales jumped 144% in 2025, from RMB 77.5M to RMB 189.1M. Even more impressive, China in-market volume was reportedly up approximately 90% YTD in 2026. The potential game changer is NRDL inclusion, which I believe is increasingly likely for 2027. If that happens, VASCEPA moves from primarily private-market access toward national reimbursement covering roughly 98% of China's population. The VASCEPA/VAZKEPA story is increasingly becoming an international growth story — and 2027 could be the inflection point. Europe/Recordati: VAZKEPA in-market demand was up approximately 69% in Q2 2026, yet Recordati has only begun rolling out the product across its territory. Canada/HLS: A much more mature market but still growing. HLS reported VASCEPA sales up 15% in Q1 2026, with unit volume up 18%. Here’s an Economic Model for 2026-2030 that you can hang your hat on! Peruse the Key Takeaways in this Illustration.
2 · Reply
EnVila
EnVila Aug. 29 at 9:22 AM
$AMRN VASCEPA’s revenue in China for the first half of 2026 reached ca. $12.7 million (RMB 85.9 million), according to Edding’s "Interim Results Announcement for the Six Months Ended 30 June 2026" released yesterday. "The gross sales revenue from the Group’s innovative drug increased by 52.2% from RMB76.1 million for the six months ended 30 June 2025 to RMB115.7 million for the Reporting Period. Of this amount, RMB85.9 million was derived from Vascepa, representing an increase of RMB13.6 million, or 18.8%, as compared with the six months ended 30 June 2025, primarily attributable to the Group’s enhanced sales and marketing efforts." https://qiniu.mfdemo.cn/yiteng/2026/08/28/tEyT6nzwDwKww.pdf
1 · Reply
CaptBeer
CaptBeer Aug. 28 at 11:09 PM
$AMRN Adherence and Legacy Effects of High Dose Eicosapentaenoic Acid in Hypertriglyceridemia and High CV Risk – REDUCE-IT Legacy https://www.amarincorp.com/news-releases/news-release-details/new-reduce-itr-legacy-analysis-presented-european-society
0 · Reply
Patrick2343
Patrick2343 Aug. 28 at 3:41 PM
$AMRN jron says wait for the new formulation only a few years away
0 · Reply
NotAgain2024
NotAgain2024 Aug. 28 at 3:29 PM
$AMRN jaja alll bull shittoo till the stock pays
0 · Reply
CostanzaGeorge
CostanzaGeorge Aug. 28 at 3:25 PM
$AMRN China market is doing better than the recent Amarin earnings have shown. Edding front loaded supply so they have not made a supply purchase in 6 consecutive quarters. First half of 2026 sales were about $12.7M which was up from $10.7M in first half of 2025. For reference, Recordati first half 2026 sales were about $16.2M. This shows there is another large market growing along with EU even with China being private pay only. Link to the report: https://qiniu.mfdemo.cn/yiteng/2026/08/28/tEyT6nzwDwKww.pdf
2 · Reply
BobGood
BobGood Aug. 28 at 2:37 PM
$AMRN The new REDUCE-IT Legacy analysis (today’s)- 1) highly adherent patients showed roughly 29–30% lower cardiovascular-event risk, and 2) the data suggest the benefit may persist even after treatment stops—though this is post-hoc/exploratory, not a new definitive endpoint. Wondering why this stock still isn’t reflecting the true value of the science and the strong technical presentations at ESC 2026. No doubt, VASCEPA is a golden asset, but it’s frustrating to see such a disconnect between its clinical capabilities, the growing body of evidence, and the market’s reaction. At some point, you’d expect the fundamentals and the science to start translating into the share price 🤞. GL
2 · Reply
Merlintrader
Merlintrader Aug. 28 at 2:21 PM
$AMRN Two things landed at once. At ESC on August 28 a new REDUCE-IT post-hoc analysis showed about 29-30% relative risk reduction in the 6,921 patients who stayed on icosapent ethyl at least 1.5 years, against 25% intention-to-treat, and a hazard ratio of 0.73 that held for years after 1,318 secondary-prevention patients stopped. Exploratory, no label change. Meanwhile Sarissa Capital cut its stake to 6.09% from 7.92%, selling 386,305 ADS on August 24-25 at about $14.00, with the strategic review still open. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/amarin-amrn-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=amarin-amrn-stock-hub
0 · Reply
Merlintrader
Merlintrader Aug. 28 at 2:12 PM
$AMRN 30%! And to think that years ago the FDA put up so much resistance to approving Vascepa... many of those who were fiercely against it, like Adam F., should now hide in shame... Fish Oil ...yes.
1 · Reply
Bulltrader988
Bulltrader988 Aug. 28 at 1:32 PM
$AMRN 👃👀 https://www.stocktitan.net/news/AMRN/new-reduce-it-legacy-analysis-presented-at-european-society-of-51zhf6acnk68.html
1 · Reply
DoMoreCharity
DoMoreCharity Aug. 28 at 1:18 PM
$AMRN https://x.com/amarincorp/status/2093313400696672469?s=46
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 28 at 12:58 PM
$AMRN https://www.amarincorp.com/news-releases/news-release-details/new-reduce-itr-legacy-analysis-presented-european-society
0 · Reply
focafoca99
focafoca99 Aug. 28 at 12:26 PM
$AMRN presented a new REDUCE-IT legacy analysis at ESC 2026 showing lasting CV benefit after stopping IPE. https://www.rapidticker.com/news/amrn-new-reduce-it-legacy-analysis-e4d9c5
0 · Reply
CaptBeer
CaptBeer Aug. 28 at 11:46 AM
$AMRN https://lnkd.in/p/g3DUiMGM
0 · Reply
DerErsteAmnesius
DerErsteAmnesius Aug. 28 at 11:11 AM
$AMRN Since all my other stocks and ETFs—with just one exception—have generated very good gains over the last 5 years, and I’ll be realizing some of them soon, this would be a good opportunity to offload my Amarin shares and offset the loss; the resulting tax refund and remaining value could then be reinvested instead. That is my Plan A—assuming no miracle occurs—though I’m not saying exactly when I’ll do it. The entire market access by R-it was botched—a complete disaster!
0 · Reply
EnVila
EnVila Aug. 28 at 6:25 AM
$AMRN People are panicking over the latest Sarissa filing, but their reporting history tells a different story. Even if it appears they reduced their position, Sarissa has made similar filings before, just shifting shares among different entities they own, not actually cutting their stake.
3 · Reply
zara12
zara12 Aug. 28 at 4:26 AM
$AMRN why ?
1 · Reply
TraderRapp
TraderRapp Aug. 28 at 2:51 AM
$AMRN so is selling finished now? Can it go up now?
0 · Reply